Other presentations
While the most common presentation of typical CIDP is of chronic progressive symmetrical weakness, patients may present with a relapsing and remitting or stepwise course, which are more common with earlier age of onset.[3]Dyck PJB, Tracy JA. History, diagnosis, and management of chronic inflammatory demyelinating polyradiculoneuropathy. Mayo Clin Proc. 2018 Jun;93(6):777-93.
https://www.mayoclinicproceedings.org/article/S0025-6196(18)30236-2/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/29866282?tool=bestpractice.com
[4]McCombe PA, Pollard JD, McLeod JG. Chronic inflammatory demyelinating polyradiculoneuropathy: clinical and electrophysiological study of 92 cases. Brain. 1987 Dec;110 (Pt 6):1617-30.
http://www.ncbi.nlm.nih.gov/pubmed/3427403?tool=bestpractice.com
[5]Hattori N, Misu K, Koike H, et al. Age of onset influences clinical features of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci. 2001 Feb 15;184(1):57-63.
http://www.ncbi.nlm.nih.gov/pubmed/11231033?tool=bestpractice.com
[6]Said G. Chronic inflammatory demyelinative polyneuropathy. J Neurol. 2002 Mar;249(3):245-53.
http://www.ncbi.nlm.nih.gov/pubmed/11993521?tool=bestpractice.com
Subacute presentation over 4-8 weeks may make distinction between CIDP and Guillain-Barre syndrome difficult.[3]Dyck PJB, Tracy JA. History, diagnosis, and management of chronic inflammatory demyelinating polyradiculoneuropathy. Mayo Clin Proc. 2018 Jun;93(6):777-93.
https://www.mayoclinicproceedings.org/article/S0025-6196(18)30236-2/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/29866282?tool=bestpractice.com
[5]Hattori N, Misu K, Koike H, et al. Age of onset influences clinical features of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci. 2001 Feb 15;184(1):57-63.
http://www.ncbi.nlm.nih.gov/pubmed/11231033?tool=bestpractice.com
[7]Oh SJ, Kurokawa K, de Almeida DF, et al. Subacute inflammatory demyelinating neuropathy. Neurology. 2003 Dec 9;61(11):1507-12.
http://www.ncbi.nlm.nih.gov/pubmed/14663033?tool=bestpractice.com
A subacute monophasic presentation is more common in children, adolescents, and young adults, who often respond well to immunomodulating therapy.[8]Nevo Y, Pestronk A, Kornberg AJ, et al. Childhood chronic inflammatory demyelinating neuropathies: clinical course and long-term follow-up. Neurology. 1996 Jul;47(1):98-102.
http://www.ncbi.nlm.nih.gov/pubmed/8710133?tool=bestpractice.com
[9]Simmons Z, Wald JJ, Albers JW. Chronic inflammatory demyelinating polyradiculoneuropathy in children: I. Presentation, electrodiagnostic studies, and initial clinical course, with comparison to adults. Muscle Nerve. 1997 Aug;20(8):1008-15.
http://www.ncbi.nlm.nih.gov/pubmed/9236792?tool=bestpractice.com
There are several CIDP variants. Pure sensory presentation may occur, with distal sensory loss and pain or with a sensory ataxia, but no muscle weakness. In sensory-predominant CIDP, motor demyelination is found on electrodiagnostic studies and weakness may develop as the course becomes more chronic.[1]Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force - second revision. Eur J Neurol. 2021 Nov;28(11):3556-83.
https://onlinelibrary.wiley.com/doi/10.1111/ene.14959
http://www.ncbi.nlm.nih.gov/pubmed/34327760?tool=bestpractice.com
Patients with pure motor CIDP have relatively symmetrical proximal and distal weakness, but normal sensation clinically and electrodiagnostically. Care must be taken to differentiate from multifocal motor neuropathy, in which weakness is asymmetrical and mainly affects the upper limbs. Corticosteroids may cause deterioration in patients with motor CIDP.[1]Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force - second revision. Eur J Neurol. 2021 Nov;28(11):3556-83.
https://onlinelibrary.wiley.com/doi/10.1111/ene.14959
http://www.ncbi.nlm.nih.gov/pubmed/34327760?tool=bestpractice.com
Distal CIDP (also called distal acquired demyelinating symmetrical neuropathy) must be distinguished from the neuropathy associated with myelin-associated glycoprotein.[1]Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force - second revision. Eur J Neurol. 2021 Nov;28(11):3556-83.
https://onlinelibrary.wiley.com/doi/10.1111/ene.14959
http://www.ncbi.nlm.nih.gov/pubmed/34327760?tool=bestpractice.com
[10]Mygland A, Monstad P. Chronic acquired demyelinating symmetric polyneuropathy classified by pattern of weakness. Arch Neurol. 2003 Feb;60(2):260-4.
https://jamanetwork.com/journals/jamaneurology/fullarticle/783675
http://www.ncbi.nlm.nih.gov/pubmed/12580713?tool=bestpractice.com
[11]Steck AJ. Anti-MAG neuropathy: from biology to clinical management. J Neuroimmunol. 2021 Dec 15;361:577725.
https://www.jni-journal.com/article/S0165-5728(21)00252-6/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/34610502?tool=bestpractice.com
Besides the lack of proximal weakness, this presentation differs from classic CIDP in that there is often a monoclonal protein, cerebrospinal fluid protein is usually not elevated, the course is rarely relapsing/remitting, and there is often a poor response to immunosuppressive medication (when a monoclonal protein is present).[10]Mygland A, Monstad P. Chronic acquired demyelinating symmetric polyneuropathy classified by pattern of weakness. Arch Neurol. 2003 Feb;60(2):260-4.
https://jamanetwork.com/journals/jamaneurology/fullarticle/783675
http://www.ncbi.nlm.nih.gov/pubmed/12580713?tool=bestpractice.com
CIDP that presents with multifocal asymmetrical weakness and numbness that begins distally, often in one limb, and spreads proximally to involve several limbs is termed multifocal CIDP (also known as multifocal demyelinating neuropathy with persistent conduction block, Lewis-Sumner syndrome; multifocal acquired demyelinating sensory and motor neuropathy [MADSAM]; multifocal inflammatory demyelinating neuropathy).[1]Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force - second revision. Eur J Neurol. 2021 Nov;28(11):3556-83.
https://onlinelibrary.wiley.com/doi/10.1111/ene.14959
http://www.ncbi.nlm.nih.gov/pubmed/34327760?tool=bestpractice.com
[12]Lewis RA, Sumner AJ, Brown MJ, et al. Multifocal demyelinating neuropathy with persistent conduction block. Neurology. 1982 Sep;32(9):958-64.
http://www.ncbi.nlm.nih.gov/pubmed/7202168?tool=bestpractice.com
[13]Saperstein DS, Amato AA, Wolfe GI, et al. Multifocal acquired demyelinating sensory and motor neuropathy: the Lewis-Sumner syndrome. Muscle Nerve. 1999 May;22(5):560-6.
http://www.ncbi.nlm.nih.gov/pubmed/10331353?tool=bestpractice.com
Rare cases may present with asymmetrical weakness and sensory loss only of the arms, known as focal CIDP or focal upper limb demyelinating neuropathy.[1]Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force - second revision. Eur J Neurol. 2021 Nov;28(11):3556-83.
https://onlinelibrary.wiley.com/doi/10.1111/ene.14959
http://www.ncbi.nlm.nih.gov/pubmed/34327760?tool=bestpractice.com
[14]Thomas PK, Claus D, Jaspert A, et al. Focal upper limb demyelinating polyneuropathy. Brain. 1996 Jun;119 (Pt 3):765-74.
https://academic.oup.com/brain/article/119/3/765/396265
http://www.ncbi.nlm.nih.gov/pubmed/8673489?tool=bestpractice.com